Literature DB >> 15992782

Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.

Kizhakke M Sindhu1, Karuppagounder S Saravanan, Kochupurackal P Mohanakumar.   

Abstract

A mitochondrial complex-I inhibitor, rotenone was unilaterally infused into the substantia nigra pars compacta (SNpc) or median forebrain bundle (MFB) to create hemiparkinsonian animal models and investigated spontaneous and drug-induced stereotypic rotations, as well as certain postural behaviors in Sprague-Dawley rats. Animals infused intranigrally, but not intra-MFB, with rotenone exhibited spontaneous contralateral rotations immediately after recovery from anesthesia. Head position bias and elevated body swing test showed insignificant contralateral bias in animals with nigral damage but a significant ipsilateral bias in MFB-lesioned rats. General motor activity of the animals was reduced in both the groups as indicated by reduced performance on a Plus-Maze. Intranigrally, rotenone-infused animals exhibited progressive ipsilateral rotations when challenged with d-amphetamine on the 7th, 14th, 21st, and 28th days or with apomorphine on 9th, 16th, 23rd, and 30th days. However, animals that received rotenone in MFB exhibited ipsilateral or contralateral rotations when challenged respectively with d-amphetamine or apomorphine only in the 5th week (28th and 30th days). Stereotaxic administration of rotenone into SNpc or MFB caused a significant loss of dopamine in the ipsilateral striatum (>80% in SNpc; >95% in MFB), when assayed employing an HPLC equipped with electrochemical detector on the 32nd day. Neuronal loss in SNpc was confirmed in coronal sections stained with cresyl violet and revealed extension of lesion towards SN pars reticulata, in SNpc-infused animals. Our results demonstrate that rotenone-induced neurodegeneration is a slow, yet progressive process similar to that in idiopathic Parkinson's disease and unlike that observed in other classical neurotoxin-mediated lesions which are abrupt and developed in few hours to days. Thus, intranigral or intra-MFB infusion of rotenone could be used for producing hemiparkinsonian animal models in rats. These findings further suggest that, while both d-amphetamine and apomorphine-induced stereotypic rotations could be used as a valuable behavioral assay procedure to test novel drugs against Parkinson's disease, yet apomorpine-induced contralateral bias in turning is a reliable indicator of specific destruction in nigrostriatal pathway and development of postsynaptic dopamine receptor supersensitivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15992782     DOI: 10.1016/j.brainres.2005.05.051

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Rotenone exerts developmental neurotoxicity in a human brain spheroid model.

Authors:  David Pamies; Katharina Block; Pierre Lau; Laura Gribaldo; Carlos A Pardo; Paula Barreras; Lena Smirnova; Daphne Wiersma; Liang Zhao; Georgina Harris; Thomas Hartung; Helena T Hogberg
Journal:  Toxicol Appl Pharmacol       Date:  2018-02-08       Impact factor: 4.219

Review 2.  Targeted delivery of nano-therapeutics for major disorders of the central nervous system.

Authors:  Huile Gao; Zhiqing Pang; Xinguo Jiang
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

3.  Striatal neuroprotection with methylene blue.

Authors:  J C Rojas; N Simola; B A Kermath; J R Kane; T Schallert; F Gonzalez-Lima
Journal:  Neuroscience       Date:  2009-07-24       Impact factor: 3.590

Review 4.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

5.  Reversible unilateral nigrostriatal pathway inhibition induced through expression of adenovirus-mediated clostridial light chain gene in the substantia nigra.

Authors:  Jun Yang; Qingshan Teng; Mary E Garrity-Moses; Shearwood McClelland; Thais Federici; Erin Carlton; Jonathon Riley; Nicholas M Boulis
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

6.  Investigate the chronic neurotoxic effects of diquat.

Authors:  Senthilkumar S Karuppagounder; Manuj Ahuja; Manal Buabeid; Koodeswaran Parameshwaran; Engy Abdel-Rehman; Vishnu Suppiramaniam; Muralikrishanan Dhanasekaran
Journal:  Neurochem Res       Date:  2012-02-14       Impact factor: 3.996

7.  Nanotechnology-based drug delivery of ropinirole for Parkinson's disease.

Authors:  Emilia Barcia; Liudmila Boeva; Luis García-García; Karla Slowing; Ana Fernández-Carballido; Yaquelyn Casanova; Sofía Negro
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.

Authors:  Nian Xiong; Jinsha Huang; Zhentao Zhang; Zhaowen Zhang; Jing Xiong; Xingyuan Liu; Min Jia; Fang Wang; Chunnuan Chen; Xuebing Cao; Zhihou Liang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

9.  Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats.

Authors:  Sawsan A Zaitone; Dina M Abo-Elmatty; Shimaa M Elshazly
Journal:  Indian J Pharmacol       Date:  2012 Nov-Dec       Impact factor: 1.200

10.  Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats.

Authors:  Debasmita Tripathy; Reena Haobam; Ranju Nair; Kochupurackal P Mohanakumar
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.